If your point is that AVXL is capable of Astronomical Market Cap growth as Arrowhead Pharma I agree. But your chart is not effective in illustrating that fact. No other company could quite as directly illustrate the lows, rise, falls and subsequent vindication by Market Cap as ARWR. Your chart is actually meaningless in this regard as it charts stock price with over many years bears little to no correlation to market cap. If one examines the Market Cap graph of ARWR and AVXL they are almost identical, with the exception that ARWR finally got market recognition. 2-11-2013 ARWR market cap was $30 million then it rose spectacularly in a short amount of time to 13 months 3-3-2014 to $1,090 Mil ($1.09 Bil) then fell back to $201 Mil on 2-10-2016 after doubling to $400 mil in 8 months fell back to where AVXL is today $110 mil on 7-17-2017 in the last 14 months it has risen 16X 1600% a 16 bagger in just one year same as AVXl is capable of on "Market Recognition" Arrowhead is a Phase II clinical stage company with no approved products. ARWR market cap is now one year later $1600 Mil ($1.6 Bil) Stock price charts do not show the growth of a company well because they do not account for share structure, the number of shares outstanding this is extremely exaggerated in charts of many years. AVXL has the potential of ARWR type rapid market cap appreciation and then SOME! At some point, the AVXL Market Cap chart might look like ARWR from July 2017 to today.
LOOK at the chart, the parallels to AVXL are uncanny:
News 
Market Data 
Discover 
